Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback